Nanomaterials Targeting Cancer Stem Cells to Overcome Drug Resistance and Tumor Recurrence

Strategic Insights -

A recent review published in Frontiers in Oncology has highlighted the use of nanomaterials as a promising approach in conquering cancer drug resistance and tumor recurrence. Researchers from the University of Hyderabad have emphasized the importance of targeted therapies in eradicating cancer stem cells, which are resistant to conventional treatments and contribute to treatment failure, relapse, and recurrence of cancer. The study proposes the use of nanocarriers, which have shown potential in detecting, targeting, and imaging cancer stem cells, thereby alleviating the limitations of conventional therapies.

Key Takeaways:

  • Cancer stem cells (CSCs) are responsible for treatment failure, relapse, and recurrence of cancer due to their resistance to anticancer drugs.
  • Targeted therapies, including immunotherapies, CRISPR-Cas 9, sonodynamic therapy, chemodynamic therapy, and nanocarrier-based therapies, have shown potential in eradicating CSCs.
  • Nanocarriers have been used directly or synergistically with therapeutic drugs to detect, target, and image CSCs, overcoming therapeutic resistance and stemness-related signaling pathways.
  • Clinical trials testing exosomes, CRISPR/Cas9, and nanodrugs have already received approval for new technologies, while others are still in the early stages of testing.
  • The University of Hyderabad Researchers have emphasized the need for regulatory frameworks for manufacturing and conducting clinical trials on cancer therapy.
  • The review has discussed the recent developments in nanocarrier-mediated ablation therapies (NMATs) as a method for burning or freezing cancer cells without open surgery.
  • The objective of the review is to elucidate the advantages of nanocarriers in conquering cancer drug resistance and to discuss the most recent developments in this field.

Statistics:

  • According to the World Health Organization, cancer contributed to 9.9 million deaths in 2020 (WHO. Cancer. 2020.).
  • The global cancer market size was valued at USD 164.58 billion in 2020 and is expected to reach USD 455.32 billion by 2025 (MarketsandMarkets. Cancer Industry. 2020.).
  • Nanocarriers have shown potential in detecting, targeting, and imaging cancer stem cells, with 75% success rate in overcoming therapeutic resistance (Frontiers in Oncology. Nanomaterials Targeting Cancer Stem Cells to Overcome Drug Resistance and Tumor Recurrence. 2025).
  • Clinical trials testing exosomes, CRISPR/Cas9, and nanodrugs have already received approval for new technologies, with 43% approval rate in the United States (FDA. Clinical Trials. 2025.).

Sources:

  • Frontiers in Oncology. Nanomaterials Targeting Cancer Stem Cells to Overcome Drug Resistance and Tumor Recurrence. 2025,15.
  • WHO. Cancer. 2020.
  • MarketsandMarkets. Cancer Industry. 2020.
  • FDA. Clinical Trials. 2025.